Ravi Kumar Paluri
Overview
Explore the profile of Ravi Kumar Paluri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi X, Su Z, Liang Z, Sun X, Luo J, Long Z, et al.
J Gastrointest Oncol
. 2024 Sep;
15(4):1962-1972.
PMID: 39279984
Background: Primary hepatic neuroendocrine carcinoma (PHNEC), which often lacks distinctive radiological features or specific clinical symptoms, is extremely rare. In this report, we describe a rare case of PHNEC that...
2.
Manne A, Esnakula A, Sheel A, Sara A, Manne U, Paluri R, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201728
Neoadjuvant therapy (NAT) for early-stage pancreatic ductal adenocarcinoma (PDA) has recently gained prominence. We investigated the clinical significance of mucin 5 AC (MUC5AC), which exists in two major glycoforms, a...
3.
Regalla D, Deep O, Paluri R
Chin Clin Oncol
. 2023 Dec;
12(6):67.
PMID: 38073310
High-grade (HG) pancreatic neuroendocrine neoplasms (PAN-NENs) are aggressive and have a poor prognosis. Yet, our understanding and treatment approaches for these tumors have rapidly evolved in the past decade, despite...
4.
Paluri R, Pulipati Y, Regalla D
Oncol Rev
. 2023 Dec;
17:11456.
PMID: 38045806
Immune checkpoint inhibitors (ICIs) have reshaped and have become a well-established treatment modality for multiple advanced-stage malignancies. ICIs block the immune system regulatory checkpoints, namely CTLA-4 and PD-1/PDL1, which provokes...
5.
Paluri R, Haris H, Li P, Gbolahan O, Jacob R, Manne U
J Gastrointest Oncol
. 2023 Nov;
14(5):2212-2220.
PMID: 37969821
Background: Gallbladder cancer is one of the highest fatal malignancy. We conducted a retrospective analysis to study the outcomes of gallbladder malignancy in an academic care setting. Methods: Data was...
6.
Manne A, Kasi A, Esnakula A, Paluri R
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175794
Mucin 5AC (MUC5AC) glycoprotein plays a crucial role in carcinogenesis and drug sensitivity in pancreatic ductal adenocarcinoma (PDAC), both individually and in combination with other mucins. Its function and localization...
7.
Odeny T, Farha N, Hildebrandand H, Allen J, Vazquez W, Martinez M, et al.
J Clin Med
. 2020 Dec;
9(12).
PMID: 33260810
There are differences in the incidence, clinical presentation, molecular pathogenesis, and outcome of colorectal cancer (CRC) based on tumor location. Emerging research suggests that the perioperative carcinoembryonic antigen (CEA) ratio...
8.
McGinnis T, Bantis L, Madan R, Dandawate P, Kumer S, Schmitt T, et al.
J Clin Med
. 2020 Sep;
9(10).
PMID: 32992976
Pancreatic intraepithelial neoplasms (PanINs) and intraductal papillary mucinous neoplasms (IPMNs) are common pancreatic adenocarcinoma precursor lesions. However, data regarding their respective associations with survival rate and prognosis are lacking. We...
9.
Regalla D, Jacob R, Manne A, Paluri R
Oncol Rev
. 2019 Oct;
13(2):440.
PMID: 31565197
Ampullary Carcinoma arises from a histologically heterogeneous region where three different epithelia converge. Even though Ampullary Carcinoma has a superior prognosis compared to pancreatic and biliary ductal neoplasms, at least...
10.
Regalla D, Williams G, Paluri R
Postgrad Med J
. 2018 Nov;
94(1118):704-708.
PMID: 30425139
Cancer immunotherapy, an area of active research, has thus far yielded several exciting breakthroughs in cancer treatment strategies. So far, immune checkpoint inhibitors have been the most promising method of...